Index Options
CME Group
Nasdaq
Cboe
TradingView
Wall Street Journal13 Analysts Have This To Say About Intellia Therapeutics
Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 6 | 4 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 1 | 0 | 0 |
| 3M Ago | 1 | 2 | 3 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $51.92, a high estimate of $91.00, and a low estimate of $14.00. Observing a downward trend, the current average is 14.77% lower than the prior average price target of $60.92.
Interpreting Analyst Ratings: A Closer Look
In examining recent analyst actions, we gain insights into how financial experts perceive Intellia Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jay Olson | Oppenheimer | Lowers | Outperform | $40.00 | $60.00 |
| Yanan Zhu | Wells Fargo | Lowers | Overweight | $60.00 | $70.00 |
| Kostas Biliouris | BMO Capital | Lowers | Outperform | $50.00 | $70.00 |
| Whitney Ijem | Canaccord Genuity | Maintains | Buy | $90.00 | $90.00 |
| Yanan Zhu | Wells Fargo | Lowers | Overweight | $70.00 | $80.00 |
| David Nierengarten | Wedbush | Maintains | Neutral | $14.00 | $14.00 |
| Geulah Livshits | Chardan Capital | Raises | Buy | $91.00 | $88.00 |
| Jay Olson | Oppenheimer | Lowers | Outperform | $60.00 | $70.00 |
| Gena Wang | Barclays | Lowers | Overweight | $55.00 | $76.00 |
| David Lebowitz | Citigroup | Lowers | Neutral | $19.00 | $25.00 |
| Salveen Richter | Goldman Sachs | Lowers | Neutral | $20.00 | $31.00 |
| Jack Allen | Baird | Lowers | Neutral | $18.00 | $24.00 |
| Geulah Livshits | Chardan Capital | Lowers | Buy | $88.00 | $94.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intellia Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intellia Therapeutics compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Intellia Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intellia Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Intellia Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Intellia Therapeutics
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Intellia Therapeutics: Delving into Financials
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Intellia Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -24.02% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Intellia Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -1489.54%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Intellia Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -14.04%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Intellia Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -11.48%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Intellia Therapeutics's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.